WAP
SYRE icon

Wealthcare Advisory Partners’s Spyre Therapeutics SYRE Stock Holding History

Wealthcare Advisory Partners’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-80
Closed -$21K – 1302
2018
Q2 		$21K Buy
+80
New +$19.7K ﹤0.01% 663

Other funds holding SYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wealthcare Advisory Partners's SYRE Position: Q3 2018 in Review

Wealthcare Advisory Partners sold out of Spyre Therapeutics (SYRE) in Q3 2018, closing a stake of 80 shares — an estimated $21K sold.

Wealthcare Advisory Partners first reported a position in SYRE in Q2 2018 and held it in 1 quarter. The position peaked at $21K in Q2 2018. 59 funds tracked by Wall St. Rank hold SYRE as of Q3 2018.

  • Wealthcare Advisory Partners reported no remaining Spyre Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Wealthcare Advisory Partners sold 80 Spyre Therapeutics shares in Q3 2018, an estimated $21K.
  • Wealthcare Advisory Partners first reported a position in Spyre Therapeutics in Q2 2018 and held it in 1 quarter.
  • Wealthcare Advisory Partners's Spyre Therapeutics position peaked at $21K in Q2 2018.
  • 59 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2018.

Based on Wealthcare Advisory Partners's 13F filing for Q3 2018, filed 14 Nov 2018.